DISPOSITION IN NORMAL VOLUNTEERS OF SODIUM AZODISALICYLATE, A POTENTIAL THERAPEUTIC AGENT IN INFLAMMATORY BOWEL-DISEASE

DISPOSITION IN NORMAL VOLUNTEERS OF SODIUM AZODISALICYLATE, A POTENTIAL THERAPEUTIC AGENT IN INFLAMMATORY BOWEL-DISEASE

Bibliographic Details
Main Authors:	Willoughby, C, Aronson, J, Agback, H, Bodin, N, Andersson, E, Truelove, S
Format:	Journal article
Language:	English
Published:	1981

Similar Items

Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis.
by: Willoughby, C, et al.
Published: (1982)

Disodium azodisalicylate in ulcerative colitis.
by: Jewell, D, et al.
Published: (1981)

THE DISPOSITION AND METABOLISM OF SULPHASALAZINE (SALICYLAZOSULFAPYRIDINE) IN MAN
by: Khan, A, et al.
Published: (1982)

The effect of nifedipine on the disposition of strontium gluconate used as a kinetic marker for calcium in healthy volunteers.
by: Moraes, M, et al.
Published: (1991)

Extracellular Vesicles: Novel Potential Therapeutic Agents in Inflammatory Bowel Diseases
by: Irene Mignini, et al.
Published: (2023-12-01)

Therapeutic efficacy of jeoryeong-tang in dextran sulfate sodium-induced mouse model of inflammatory bowel disease
by: Il-Woong Jang, et al.
Published: (2025-01-01)

Therapeutic targets in inflammatory bowel disease
by: Daniela Fluxa, et al.
Published: (2019-07-01)

Deciphering Microbial Composition in Patients with Inflammatory Bowel Disease: Implications for Therapeutic Response to Biologic Agents
by: Orazio Palmieri, et al.
Published: (2024-06-01)

Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?
by: Chang Soo Eun
Published: (2017-01-01)

Using systems medicine to identify a therapeutic agent with potential for repurposing in inflammatory bowel disease
by: Katie Lloyd, et al.
Published: (2020-11-01)

Bicervical Normal Uterus with Normal Vagina and Anteroposterior Disposition of the Double Cervix
by: José Morales-Roselló, et al.
Published: (2011-01-01)

The discovery of the foxglove as a therapeutic agent
by: Aronson, J
Published: (1987)

Therapeutic Drug Monitoring in Inflammatory Bowel Disease
by: Manoel Alvaro de Freitas Lins Neto, et al.
Published: (2023-12-01)

Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases
by: Marafini I, et al.
Published: (2020-06-01)

Evolving Therapeutic Strategies in the Inflammatory Bowel Disease
by: Soo-Young Na, et al.
Published: (2018-02-01)

Sodium phosphate solution as bowel preparation for outpatient diagnostic and therapeutic manipulations
by: N. V. Topchy, et al.
Published: (2017-12-01)

Advances in biological agents in the treatment of inflammatory bowel disease
by: Na LI, et al.
Published: (2022-08-01)

The Role of Biologics Agent in the Treatment of Inflammatory Bowel Disease
by: Tri Hapsoro Guno, et al.
Published: (2017-12-01)

Neurochemical studies in normal volunteers
by: Nutt, D, et al.
Published: (1988)

Therapeutic Potential of Triptolide as an Anti-Inflammatory Agent in Dextran Sulfate Sodium-Induced Murine Experimental Colitis
by: Bufu Tang, et al.
Published: (2020-11-01)

Translating immunology into therapeutic concepts for inflammatory bowel disease
by: Uhlig, HH, et al.
Published: (2018)

Genetically engineered bacteria as inflammatory bowel disease therapeutics
by: Zhen-Ping Zou, et al.
Published: (2024-12-01)

Ferroptosis: A therapeutic opportunity of inflammatory bowel disease
by: Yulin Ye, et al.
Published: (2024-04-01)

Endoscopic Therapeutic Approach for Dysplasia in Inflammatory Bowel Disease
by: Sung Noh Hong
Published: (2017-09-01)

Inflammasome Regulation: Therapeutic Potential for Inflammatory Bowel Disease
by: Qiuyun Xu, et al.
Published: (2021-03-01)

Editorial: Novel Therapeutic Approaches in Inflammatory Bowel Diseases
by: Giovanni Pallio
Published: (2023-09-01)

Gut microbiome–based therapeutics in inflammatory bowel disease
by: Kelly A. Hu, et al.
Published: (2023-04-01)

Nutritional approach as therapeutic manipulation in inflammatory bowel disease
by: Jin Young Yoon
Published: (2019-10-01)

The Gut Microbiota in the Pathogenesis and Therapeutics of Inflammatory Bowel Disease
by: Tao Zuo, et al.
Published: (2018-09-01)

Development of Ac2-26 Mesoporous Microparticle System as a Potential Therapeutic Agent for Inflammatory Bowel Diseases
by: Broering MF, et al.
Published: (2024-04-01)

THE DISPOSITION OF ORAL RUBIDIUM CHLORIDE IN ESSENTIAL-HYPERTENSION
by: Boon, N, et al.
Published: (1982)

The dispositional effects of holidays on investor sentiment: Therapeutic and hygienic
by: Qing Liu, et al.
Published: (2023-04-01)

CYP2B6*6 genotype specific differences in artemether‐lumefantrine disposition in healthy volunteers
by: Abdullahi, ST, et al.
Published: (2019)

Comparable Bioavailability and Disposition of Pefloxacin in Patients with Cystic Fibrosis and Healthy Volunteers Assessed via Population Pharmacokinetics
by: Jürgen B. Bulitta, et al.
Published: (2019-07-01)

Respiratory burst activity of intestinal macrophages in normal and inflammatory bowel disease.
by: Mahida, Y, et al.
Published: (1989)

Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
by: Al Sulais E, et al.
Published: (2020-01-01)

THE EFFECT OF DIGOXIN ON THE INVIVO DISPOSITION OF AN ORAL LOAD OF RUBIDIUM CHLORIDE
by: Aronson, J, et al.
Published: (1982)

Agentes biológicos en enfermedad inflamatoria intestinal Biological agents in inflammatory bowel disease
by: M. Van Domselaar
Published: (2008-12-01)

Telocytes in inflammatory bowel diseases: contributions to pathology and therapeutic potentials
by: Ronaldo Paolo Panganiban, et al.
Published: (2025-01-01)

Inflammatory Bowel Disease Therapeutics: A Focus on Probiotic Engineering
by: Jayshree Mishra, et al.
Published: (2022-01-01)